IFPA

Global leader in fighting psoriatic disease
(1)

Vision

A future where all people living with psoriatic disease enjoy good health and wellbeing, free from stigma and preventable disability and comorbidities

Mission

Unite, strengthen and lead the global psoriatic disease community to improve the lives of all people affected by psoriatic disease.

13/03/2026

We are honored to introduce the Scientific Executive Committee for the IFPA Conference 2027 – a group of internationally respected experts driving innovation and scientific excellence in the field.

✔️Jo Lambert – is a Senior Full Professor in Dermatology and Venereology, she specializes in the fields of immune dermatoses. Her research interests lie in the improvement of care in immune-mediated inflammatory skin conditions.

✔️Joel M. Gelfand – Professor, internationally recognized expert in psoriasis, epidemiology, drug safety, and clinical trials.

✔️Vinod Chandran – Professor of Medicine at the University of Toronto, a rheumatologist and expert on psoriatic arthritis, clinician scientist.

Their combined expertise will help shape a world-class scientific program for IFPA Conference 2027 – the only global scientific event dedicated to frontline research in psoriasis, psoriatic arthritis and related fields.

👉 Discover more on the IFPA Conference website: https://eu1.hubs.ly/H0sDZ070

05/03/2026

Did you know that every medical breakthrough begins with clinical trials?

Before a new treatment or medicine reaches patients, it goes through multiple stages of clinical trials. These studies follow strict scientific and ethical standards—and they rely on people who choose to take part and contribute to medical progress.

But here’s the challenge: many people have never heard about clinical trials, or find them difficult to understand. The language used by scientists and clinical research teams can feel confusing or unfamiliar, making it harder for people to learn about opportunities to participate.

As part of our Breaking Barriers project, we’re exploring what prevents diverse communities and social groups from participating in clinical trials. One key barrier we’ve identified is language. 💬

Understanding the terminology can empower people to make informed decisions about participating in research.

That’s why we’re creating a Glossary of Common Terms in Clinical research – a resource designed to make the language of clinical research clearer and easier to navigate.

Stay tuned for the launch of our glossary!

Together, we can break barriers and build more inclusive medical research.

👉 Read more: https://eu1.hubs.ly/H0sljCP0

04/03/2026

Today is World Obesity Day. 🌍

Nearly 3 billion people worldwide are living with overweight and obesity. By 2035, that number could rise to 4 billion — almost half of the global population. Among children, rates are rising rapidly, with 1 in 5 now living with obesity.

Obesity does not occur or exist in isolation.

Obesity is a complex, chronic disease and a major driver of other noncommunicable diseases (NCDs), affecting overall health and quality of life in profound ways.

What is rarely discussed is the close connection between obesity and psoriatic disease. Psoriasis and psoriatic arthritis are driven by systemic inflammation — and people living with these conditions have a higher risk of developing obesity. In turn, obesity can worsen inflammatory pathways and impact disease severity and treatment outcomes.

The powerful link between obesity and mental health should not be underestimated. Weight-based discrimination remains widespread, contributing to stigma and isolation, deepening inequalities, and increasing the risk of depression, anxiety, and other mental health challenges.

No one should have to navigate a chronic disease while also carrying the weight of stigma.

We can rewrite the story of obesity — together — by recognizing its complexity, addressing its links to other chronic conditions, and putting dignity and empathy at the center of the conversation.

Want to know more about the link between psoriasis, obesity and other noncommunicable diseases?
👉 Read our report: https://eu1.hubs.ly/H0sjf_W0

03/03/2026

🌟 Save the Date for IFPA Conference 2027! 🌟

We are proud to announce the theme of the next IFPA Conference:
✨ From Burden to Breakthrough: Bridging Science, Innovation and Patient-Centered Care ✨

📅 May 20–22, 2027
📍 Waterfront Congress Centre, Stockholm

Get ready for the 8th World Psoriasis & Psoriatic Arthritis Conference — the only global multidisciplinary scientific event dedicated to cutting-edge research in psoriasis, psoriatic arthritis, and related fields.

Bringing together leading experts in dermatology, rheumatology, and beyond, this conference will provide a dynamic platform to:

🔬 Exchange groundbreaking research
🌍 Deepen understanding of psoriatic disease and its comorbidities
💡 Explore innovation and collaboration opportunities
🤝 Strengthen patient-centered approaches to care

📅 Important Dates
• September 1, 2026 – Registration opens
• October 1, 2026 – Abstract submission opens

👉 Learn more and stay updated:
https://eu1.hubs.ly/H0sgb0z0

28/02/2026

🌍 Rare is many.
Over 300 million people live with rare diseases – yet too often, their voices are not heard. Today, on , IFPA stands with everyone living with rare diseases, their families and caregivers, including people with rare forms of psoriasis.

Prevalence shouldn’t determine care. Everyone deserves equal access to treatment and support. 💙

Rare Disease Day

27/02/2026

On February 26, IFPA had the privilege to attend “More Than Just Skin” at the European Parliament — a historic high-level discussion on skin diseases.

Following the 2025 WHA Resolution recognizing skin diseases as a global health priority, this event brought together policymakers, clinicians, and patient advocates to discuss how skin health must be integrated into Europe’s broader health agenda.

Moderated by Eva Kopacz, Vice-President of the European Parliament, Elzbieta Lukacijewska, MEP, and Dr. Branka Marinovic (EADV), the session emphasized that skin diseases are not just medical issues — they affect dignity, mental health, productivity, and social inclusion.

A powerful testimony came from Dirk Provez, who shared his personal journey of living with psoriasis. Dirk described chronic pain, relentless itching, and sleep deprivation, explaining how delays in accessing effective biologic therapy resulted in over a year of lost work and significant financial loss for the family. His testimony brought the human, social, and economic impact of skin diseases into sharp focus.

It was truly inspiring to see psoriasis take an important place in the European Parliament and on the European health agenda.

Dr. Claire Fuller, Chair of the International Foundation for Dermatology, highlighted the importance of gender lens looking at the impact of skin diseases, stressing that they drive social inequalities, workforce exclusion, and lost productivity — particularly for women.

Jennifer Austin, CEO of GlobalSkin, highlighted that skin diseases are consistently under-recognized and underfunded. She called for better data collection, and patient empowerment.

Other key messages included:
🔸Over 88% of people living with skin diseases experience daily shame — an unacceptable percentage.
🔸Visibility of skin diseases often leads to stigma, discrimination, and social isolation, requiring urgent action.
🔸Mental health support, school-based education and prevention strategies are critical.

The discussion reiterated that skin diseases can no longer be treated as a marginal issue — implementation of the WHA resolution is now the priority.

We will closely follow the outcomes and the next steps of the discussion for the global psoriasis community.

25/02/2026

Ahead of Rare Disease Day, on February 28, we’d like to raise awareness of rare forms of psoriatic disease that too often go unseen and unheard.

One of these is Generalized Pustular Psoriasis (GPP) — a rare, severe, and potentially life-threatening form. Globally, it affects an estimated 1–9 people per million, with some regional variation. It is more common in women and most often appears in midlife.

Beyond the numbers lies a reality many don’t see: living with a rare disease can be a very overwhelming and isolating experience.

Several years ago Kate Reynolds The Lavender Librarian, a children’s librarian from Ontario, Canada, experienced her first outbreak of GPP. It was nearly fatal — and it profoundly changed her life.

When Kate tried to explain her diagnosis to her employer, she faced another challenge: limited awareness and understanding of psoriatic disease. What she experienced is common among people living with rare conditions — the burden of not only managing a serious illness but also educating others about it.

Determined to make a difference, Kate joined the work of International Federation of Psoriasis Associations (IFPA) to raise awareness of psoriatic disease and to advocate for better health and wellbeing for everyone living with it.

🎥 Listen to Kate as she reflects on her first outbreak of GPP, the impact it had on her work life, and why awareness matters. This Rare Disease Day, let’s amplify the voices of those living with rare conditions.

Read more here:
https://eu1.hubs.ly/H0s5c150

20/02/2026

Rare Disease Day – February 28

Over 300 million people worldwide live with a rare disease — that’s about 1 in 25 people.

Many know the most common form of psoriasis — plaque psoriasis or psoriasis vulgaris, which causes itchy, flaky patches. But psoriatic disease is a spectrum, with several lesser-known forms.

About 3% of people with psoriasis develop pustular psoriasis, including:
🔸Generalized pustular psoriasis (GPP) – a life-threatening condition where the skin becomes intensely red, painful, and can peel in large areas.
🔸Palmoplantar pustulosis (PPP) – painful inflammation on the hand palms and feet soles.
🔸Acrodermatitis continua of Hallopeau (ACH) – affecting fingers, toes, and nails.

Other rare, serious forms include:
🔸Erythrodermic psoriasis, characterized by fiery red skin across the body, increased heart rate, severe itching, and temperature changes.
🔸Arthritis mutilans – a severe, deforming form of psoriatic arthritis.

This Rare Disease Day, we stand with everyone living across the psoriatic disease spectrum, along with their families, friends, and caregivers.

💜 Join us in raising awareness for every form of psoriatic disease.

👉 Read more here:
https://eu1.hubs.ly/H0rZJRT0

19/02/2026

A major milestone for the global psoriasis community.
Last week in Geneva, IFPA (the International Federation of Psoriasis Associations) signed a multi-year collaboration agreement with the WHO Foundation — a significant step forward in strengthening global action on psoriasis and psoriatic arthritis.

This partnership aims to support WHO-led efforts to improve access to diagnosis and care for people living with psoriatic disease worldwide.

🎥 Watch the video to hear the reflections of Frida Dunger, IFPA's Executive Director, and learn what this collaboration means for millions of people around the world.

📄Read the article: https://eu1.hubs.ly/H0rY5yg0

11/02/2026

For many people with psoriatic disease, conversations with doctors often stay focused on the skin, but there is much more to understand.

In episode 4 of Beyond The Flare, dermatologist, Dr. Álvaro González Cantero-Dermatólogo discusses why looking beyond visible symptoms and recognizing comorbidities is essential.

Listen now:
Spotify: https://eu1.hubs.ly/H0rFSm30
Apple Podcasts: https://eu1.hubs.ly/H0rFR5Y0

09/02/2026

An important step for the global psoriasis community.

IFPA and WHO Foundation have signed a collaboration agreement to support WHO-led efforts to strengthen understanding, diagnosis and care for psoriatic disease.

Why does this collaboration matter?
Despite its global prevalence, psoriatic disease remains widely under-recognized, and many countries lack reliable epidemiological data to inform diagnosis, care and policy decisions. According to the Global Psoriasis Atlas, only about 20 percent of countries currently have data on psoriasis.

It has been nearly a decade since the Global Report on Psoriasis helped elevate psoriasis on the global health agenda. Since then, research has further clarified links between psoriatic disease and other chronic conditions, alongside advances in treatment and care.

As part of this collaboration, IFPA will support WHO-led work, including the planned update of the Global Report on Psoriasis published in 2016, incorporating new data and scientific advances.

Additional areas of focus include:
🔹Sharing evidence-based guidance with countries
🔹Supporting WHO-aligned digital tools that strengthen earlier recognition of psoriatic disease, particularly in low-resource settings
🔹Contributing to education and training efforts for healthcare professionals

We look forward to collaborating to help strengthen health systems and improve care for people living with psoriatic disease.

👉 Read more on our website: https://eu1.hubs.ly/H0rzS-r0

04/02/2026

Today, on World Cancer Day, we stand in solidarity with the global cancer community, including those living with cancer, cancer survivors, and the families and communities who support them.

We also want to highlight that cancer is a serious yet lesser-known comorbidity of psoriatic disease. Chronic systemic inflammation, along with some long-term immunosuppressive therapies, may increase cancer risk, especially for skin cancers and lymphoma.

Regular screenings and proactive health checks are essential for early detection and prevention. Understanding the link between inflammation and cancer is a critical step toward timely intervention.

Adress

Slottsbacken 8
Stockholm
SE-16751

Webbplats

http://www.ifpa-pso.com/

Aviseringar

Var den första att veta och låt oss skicka ett mail när IFPA postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Markerad

2Heal Medical
Drottninggatan 101

Vill du placera din praktik längst upp i Klinik-listan i Stockholm?

Dela

Typ

Medicin och hälsa